

Menin (1-300): sc-4321 WB

BACKGROUND

Menin (multiple endocrine neoplasia I, MEN1, MEAI, SCG2) is a nuclear tumor suppressor that is mutated in patients with multiple endocrine neoplasia type I (MEN1). Menin can activate the transcription of differentiation-regulating genes by covalent histone modification. In osteoblasts, the interaction of Menin and the TGF β /Smad3 pathway negatively regulates BMP2/Smad1/5- and Runx2-dependent transcription activities leading to inhibition of late-stage differentiation. Menin regulates the expression of IGFBP-2 by adenoviruses induces apoptosis in murine embryonic fibroblasts in a Bax/Bak-dependent manner. Two mRNA exist and two variants of the shorter mRNA have alternative splicing that changes the CDS. Five variants where alternative splicing takes place in the 5' UTR have been identified.

REFERENCES

1. Komminoth, P. 1997. Multiple endocrine neoplasia type 1 and 2. 1997 diagnostic guidelines and molecular pathology. *Pathologie* 18: 286-300.
2. Mayr, B., Apenberg, S., Rothamel, T., von zur Muhlen, A., and Brabant, G. 1997. Menin mutations in patients with multiple endocrine neoplasia type 1. *Eur. J. Endocrinol.* 137: 684-687.
3. Debelenko, I.V., Brambilla, E., Agarwal, S.K., Swalwell, J.I., Kester, M.B., Lubensky, I.A., Zhuang, Z., Guru, S.C., Manickam, P., Olufemi, S.E., Chandrasekharappa, S.C., Crabtree, J.S., Kim, Y.S., Heppner, C., Burns, A.L., Spiegel, A.M., Marx, S.J., Liotta, L.A., Collins, F.S., Travis, W.D., and Emmert-Buck, M.R. 1997. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. *Hum. Mol. Genet.* 6: 2285-2290.
4. Guru, S.C., Goldsmith, P.K., Burns, A.L., Marx, S.J., Spiegel, A.M., Collins, F.S., Chandrasekharappa, S.C. 1998. Menin, the product of the MEN1 gene, is a nuclear protein. *Proc. Natl. Acad. Sci. USA* 95: 1630-1634.
5. Chakrabarti, R., Srivatsan, E.S., Wood, T.F., Eubanks, P.J., Ebrahimi, S.A., Gatti, R.A., Passaro, E. Jr., Sawicki, M.P. 1998. Deletion mapping of endocrine tumors localizes a second tumor suppressor gene on chromosome band 11q13. *Genes Chromosomes Cancer* 22: 130-137.
6. Shan, L., Nakamura, Y., Nakamura, M., Yokoi, T., Tsujimoto, M., Arima, R., Kameya, T., and Kakudo, K. 1998. Somatic mutations of multiple endocrine neoplasia type 1 gene in the sporadic endocrine tumors. *Lab. Invest.* 78: 471-475.
7. Naito, J., Kaji, H., Sowa, H., Hendy, G.N., Sugimoto, T., Chihara, K. 2005. Menin suppresses osteoblast differentiation by antagonizing the AP-1 factor, JunD. *J. Biol. Chem.* 280: 4785-4791.
8. Milne, T.A., Hughes, C.M., Lloyd, R., Yang, Z., Rozenblatt-Rosen, O., Dou, Y., Schnepp, R.W., Krankel, C., Livolsi, V.A., Gibbs, D., Hua, X., Roeder, R.G., Meyerson, M., Hess, J.L. 2005. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. *Proc. Natl. Acad. Sci. USA* 102: 749-754

SOURCE

Menin (1-300) is produced in *E. coli* as a 60 kDa tagged fusion protein corresponding to amino acids 1-300 of Menin of human origin.

PRODUCT

Menin (1-300) is purified from bacterial lysates (>98%) by column chromatography; supplied as 10 μ g in 0.1 ml SDS-PAGE loading buffer.

APPLICATIONS

Menin (1-300) is suitable as a Western blotting control for sc-5566 and sc-8201.

STORAGE

Store at -20° C; stable for one year from the date of shipment.

RESEARCH USE

For research use only, not for use in diagnostic procedures.